SOLICITATION NOTICE
H -- Molecular diagnostic testing for mutations in BRCA1 and BRCA2
- Notice Date
- 8/15/2003
- Notice Type
- Solicitation Notice
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- Reference-Number-NCI-30115-NV
- Response Due
- 8/22/2003
- Archive Date
- 9/6/2003
- Point of Contact
- Deborah Moore, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Caren Rasmussen, Lead Contract Specialist, Phone (301) 402-4509, Fax (301) 402-4513,
- E-Mail Address
-
dm170b@nih.gov, cr214i@nih.gov
- Description
- The National Cancer Institute (NCI), Center for Cancer Research (CCR), Genetics Branch (GB) plans to procure on a sole source basis with Myriad Genetic Laboratories Inc., 320 Wakara Way, Salt Lake city, UT 84108, for the continued molecular diagnostic testing for mutations in BRCA1 and BRCA2 using its patented BRACAnalysis. The Clinical Cancer Genetics Program within the Genetics Branch, CCR, NCI, is dedicated to the study of the causes and consequences of cancer-associated genetic instability. The goal is to determine the distinctive versus unifying themes among several types of genetic instability implicated in carcinogenesis and associated clinical implications. This contract will be used to perform genetic testing for mutations in BRCA1 and BRCA2. Full gene sequencing is the method employed on a clinical basis and is the most sensitive testing widely available thus far to identify mutations in BRCA1 or BRCA2. Sequencing is performed in both forward and reverse directions of all coding exons and adjacent base pairs in the non-coding intervening sequences. In addition, this analysis includes testing for the five specific large genomic rearrangements in BRCA1. Since this is a continuation of ongoing research it is imperative that Myriad Genetic Laboratories perform these tests as not to introduce new variables and maintain comparability across tests done at different times. This service is considered commercial as defined in FAR Part 2, and this acquisition is being made in accordance with the test program using simplified procedures for certain commercial items as authorized in FAR 13.5. This is not a solicitation for competitive quotations. However, if any interested party believes it can provide the above service, without introducing new variables into an ongoing experiment it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. An original and one copy of the capability statements must be received in the contracting office by 1:00 p.m. EDT, on August 22, 2003. All questions must be in writing and can be faxed to (301) 402-4513 or emailed to dm170b@nih.gov . It is the vendor's responsibility to call (301) 402-4509 to insure questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. NAICS 541380.
- Record
- SN00402917-W 20030817/030815213908 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |